OS Therapies (OSTX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

OSTX OS Therapies

Watchlist

3.140
+0.122+4.03%

Close Oct 16 16:00 ET

3.020
-0.120-3.82%

Post 17:18 ET

65.58MMarket Cap-10000P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | OS Therapies Shares Are Trading Higher After the Company Announced the Completion of Its Phase 2b Clinical Trial for OST+HER2 in Recurred Osteosarcoma and Is Preparing to Request an FDA Type C Meeting to Adjust Protocol. It's Data Analysis and Topline...
BenzingaOct 3 15:08 ET
12 Health Care Stocks Moving In Thursday's Intraday Session
BenzingaOct 3 12:30 ET
Express News | Os Therapies Inc - to Request Type C Meeting With FDA
ReutersOct 3 08:01 ET
Express News | Os Therapies Inc - to Ring Closing Bell at NYSE on Oct 3, 2024
ReutersOct 3 08:01 ET
Express News | Os Therapies Announces Last Patient Enrolled in Ost-Her2 Osteosarcoma Phase 2B Clinical Trial Completes Last Patient Visit
ReutersOct 3 08:00 ET
OS Therapies Is Maintained at Buy by EF Hutton
Dow JonesSep 16 12:09 ET · Ratings

Comments

Jaguar8

Sep 11 07:18

NEWS

$OS Therapies (OSTX.US)$
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancer
Strong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancer
Strong safety profile for FRA-H wit...

Jaguar8

Aug 29 06:53

NEWS

$OS Therapies (OSTX.US)$
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
OS Therapies Incorporated (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) - has received its last treatment dos...